OBJECTIVE: To assess cost-effectiveness of ezetimibe 10 mg (EZ10) co-administration with simvastatin versus a simvastatin dose titration strategy in CHD patients who do not attain cholesterol goal (TC < 5 mmol/L) with simvastatin monotherapy. METHOD: A decision-analytic model was developed to project lifetime costs and benefits of lipid therapy. Clinical trial data were used to estimate TC reductions for different treatment strategies. The effect of TC reductions on CHD event rates was estimated using Framingham equations and Hungarian National Statistics data on nonCHD-related mortality. Direct costs of CHD events in Hungary, Hungarian prices for simvastatin and EZ 10 price (based on German EZ10 price) were used to project lifetime costs. The model was run for a population consisting of 138 CHD patients who are currently treated with simvastatin in an observational Lipid Lowering Treatment study conducted in Hungary, and had not reached goal at the TC measurement after minimum 60 days of treatment. RESULTS: For these patients (mean age 62.9 years, 51% male, lipid profile on simvastatin LDL-C 3.55 mmol/l, TC 5.99 mmol/l, HDL 1.44 mmol/l, triglycerides 2.40 mmol/l), EZ10 co-administered with simvastatin compared to simvastatin titration is projected to increase life expectancy by 0.69 years with a discounted C/LY of 14,891€ and the discounted C/QALY's of 14,827€. CONCLUSIONS: Treatment with EZ10 co-administered with simvastatin for CHD patients not at goal is projected to be a more cost-effective alternative to simvastatin titration which is substantially under the limit C/LY of 30,000€. Numerous clinical studies have demonstrated the safety and effectiveness of radiofrequency catheter ablation for treatment of ventricular tachycardia (VT). The objective was to evaluate the cost effectiveness of catheter ablation relative to drug therapy to treat frequent recurrence of VT among patients with structural heart disease. METHODS: We calculated the incremental cost effectiveness of catheter ablation relative to daily amiodarone treatment over various time horizons up to 5 years using a decision analytic Markov model (DATA 4.0 TM , TreeAge Software Inc.). Costs were based on a third party payer's perspective using 2004 Medicare reimbursement schedules and discounted average wholesale drug prices. Model parameters, adverse event rates, and utility weight estimates were obtained from randomized clinical trial literature and expert opinion. Costs and effects were discounted at 3% annually and sensitivity analyses were performed. The model analyzed the outcomes and resource utilization of a hypothetical cohort of 10,000 patients with structural heart disease and implantable cardioverter-defibrillators who experience frequent VT episodes. RESULTS: Ablation consistently produced greater quality adjusted life years (QALYs) compared to amiodarone in analyses of 1 to 5 years. The incremental QALYs of ablation relative to amiodarone at 1,2 and 3-years are 0.477, 0.82 and 1.05. The average 1, 2, and 3-year costs for ablation ($14,000, $14,760, $15,330) are higher compared to amiodarone ($10,760, $12,870, $14,760). However, over a 5-year time horizon, the average cost of ablation is less than amiodarone. The incremental cost-effectiveness ratio of ablation relative to amiodarone decreases from $81,340 at 1 year to $6392 at 3 years. By 3.6 years, ablation dominates amiodarone. CONCLUSIONS: Catheter ablation treatment of VT becomes increasingly cost effective compared to drug therapy as the time horizon increases and after 3.6 years, ablation is less costly and more effective than amiodarone therapy. 4 MSD Spain, Madrid, Spain OBJECTIVES: LIFE was a double-masked, randomized trial of losartan vs. atenolol in 9193 patients with essential hypertension and LVH ascertained by electrocardiography. Losartan reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke by 13% (p = 0.021) and reduced the risk of stroke by 25% (p = 0.001), despite a similar degree of blood pressure control. Our objective was to assess the costeffectiveness of losartan compared with atenolol in hypertensive patients with LVH, from the perspective of the Spanish Health Care system. METHODS: Losartan and atenolol utilisation within the trial period and lifetime direct medical costs following a stroke in Spain were combined with estimates of reduction in life expectancy following stroke. The cumulative incidence of stroke and study medication utilization after 5.5 years of patient follow-up were separately estimated, adjusting for baseline degree of LVH and Framingham risk score. To estimate per patient lifetime stroke costs, we multiplied the cumulative incidence of stroke by the lifetime direct medical cost attributable to stroke. All costs and benefits are in 2004 Spanish prices discounted at 3% annually. RESULTS: Losartan reduced strokerelated cost by 270€ per patient due to a lower cumulative incidence of stroke at 5.5 years (4.9% vs. 6.5%; p = 0.003). Net costs were 1626€ higher per patient over 5.5 years for losartan compared with atenolol. The number of life-years gained (LYG) by preventing a stroke was 5.6 years, resulting in 0.090 (discounted) LYG per patient with losartan. The estimated cost per LYG for losartan was 18,147€ (95% CI: 10,127, 46,724) which is well within bench-mark values (30,000€/LYG) for accepted cost effective interventions in Spain. The probability of the costeffectiveness ratio falling below a threshold of 30,000€/LYG was 0.88. CONCLUSIONS: Treatment with losartan compared with atenolol over a 5.5 year period is, based on the cost per LYG, a cost-effective intervention in Spain.
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